✦ LIBER ✦

A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative

✍ Scribed by Vassiliki-Anastasia Sypsa; Konstantinos Mimidis; Nicholas C. Tassopoulos; Dimitrios Chrysagis; Themistoklis Vassiliadis; Antonios Moulakakis; Maria Raptopoulou; Caterina Haida; Angelos Hatzakis

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 428 KB
Volume: 42
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.20738

No coin nor oath required. For personal study only.

✦ Synopsis

We studied viral dynamic parameters in 44 chronic hepatitis B/hepatitis B e antigen (HBeAg)(؊) patients treated with pegylated interferon alfa-2b (PEG-IFN) 100 or 200 g weekly or lamivudine 100 mg daily or the combination of PEG-IFN 100 or 200 g with lamivudine. Patients receiving PEG-IFN monotherapy exhibited viral load oscillations between weekly injections, which were resolved by the addition of lamivudine. The median pharmacological delay was estimated at 4.1, 5.8, and 1.8 hours in PEG-IFN monotherapy, PEG-IFN 100/200 g ؉ lamivudine, and lamivudine monotherapy, respectively (P ‫؍‬ .44). The median half-life of free virus was 12.7 hours (range, 2.4-69.2 hours). The mean antiviral effectiveness of PEG-IFN 100/200 g monotherapy was lower than that of lamivudine (82.6% vs. 96.4%; P ‫؍‬ .005). The mean effectiveness of PEG-IFN 100 g ؉ lamivudine and PEG-IFN 200 g ؉ lamivudine was 92.8% and 94.4%, respectively. The half-life of infected cells ranged from 2.7 to 75 days. The median half-life of infected cells in patients receiving the combination regimens of PEG-IFN and lamivudine was similar to that of lamivudine patients (5.0 days vs. 6.0 days, P ‫؍‬ .77). In conclusion, the addition of pegylated interferon alfa-2b in lamivudine treatment was found to neither enhance the potency of blocking HBV production nor the decay rates of infected cells. Supplementary material for this article can be found on the HEPATOLOGY website (http://www.interscience.wiley.com/jpages/0270-9139/ suppmat/index.html). (HEPATOLOGY 2005;42:77-85.

📜 SIMILAR VOLUMES

Long-term outcomes of thymosin-α1 and in

Long-term outcomes of thymosin-α1 and interferon α-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B

✍ Murat Saruc; Nuri Ozden; Nurten Turkel; Semin Ayhan; Lynette M. Hock; Isil Tuzcu 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB

Hepatitis B e antibody (HbeAb) and hepatitis B virus (HBV) DNA positive chronic hepatitis is a clinical entity, distinct from classical hepatitis B e antigen (HbeAg) positive chronic hepatitis B. Our aim was to evaluate the long-term therapeutic efficacy of the combination of interferon alpha-2b and

Prediction of response during interferon

Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison

✍ M J Tong; L M Blatt; J G McHutchison; R L Co; A Conrad 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 206 KB 👁 1 views

Patients with chronic hepatitis C (n Å 103) were treated cases of acute hepatitis C occur on an annual basis, and an estimated 8,000 to 10,000 deaths occur each year of compli-for 24 weeks with interferon alfa 2b and followed up for 24 weeks after cessation of therapy (week 48). When hepatitis catio

Efficacy and tolerability of rituximab w

Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus–related vasculitis: A long-term followup study of thirty-two patients

✍ Benjamin Terrier; David Saadoun; Damien Sène; Jérémie Sellam; Laurent Pérard; Br 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 2 views

Positive and negative strand of hepatiti

Positive and negative strand of hepatitis C virus RNA sequences in peripheral blood mononuclear cells in patients with chronic hepatitis C: No correlation with viral genotypes 1b, 2a, and 2b

✍ Kao, J. H.; Chen, P. J.; Lai, M. Y.; Wang, T. H.; Chen, D. S. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 2 views

Hepatitis C virus (HCV) has many genotypes which are closely associated with the severity of chronic hepatitis and the response to antiviral therapy. Although HCV is essentially hepatotropic, several lines of evidence suggest that this virus can infect peripheral blood mononuclear cells (PBMC) in mo

Biochemical and virological outcome of p

Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: A 4-year follow-up of 211 patients

✍ E K Manesis; C Papaioannou; A Gioustozi; G Kafiri; J Koskinas; S J Hadziyannis 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB 👁 1 views

To compare two interferon (IFN) schedules for the treatment of chronic hepatitis C, we followed 211 patients who received 3 million units IFN-alpha2b thrice weekly for either 6 months (group 1; 85 patients) or 12 months (group 2; 126 patients), with a median follow-up of 3.4 (0.1-8.4) and 4.2 (0.7-8

Combined treatment with interferon alpha

Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone

✍ R. Schvarcz; Z. B. Yun; A. Sönnerborg; O. Weiland 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 442 KB 👁 1 views

Ten patients with chronic hepatitis C, six of whom had not responded and four of whom had responded in a non-sustained fashion to interferon-alpha treatment alone, were given interferon alpha-2b and ribavirin in combination during 24 weeks. Interferon alpha-2b was given subcutaneously, at a dose of